The monolayer of endothelial cells (ECs) on the internal surface of the cornea is critical to maintenance of corneal transparency and normal visual acuity. These cells have been shown to possess a metabolically coupled and osmotically active HCO
3 − transport system that regulates hydration of the corneal stroma.
1 Unlike other species in which endothelial cell replication readily occurs in vivo to maintain normal cell density,
2 3 human ECs do not undergo mitosis to any meaningful extent to replace lost or injured cells. Even in the absence of disease, there is a gradual decrease in EC density throughout life (∼4000 cells/mm
2 in infancy to ∼1500 in the elderly).
4 5 Death of ECs is also a major limiting factor in maintenance of scarce donor corneas ex vivo before transplantation, with falling EC density during storage accounting for approximately 30% of corneas being discarded, the endothelium being considered of insufficient quality for transplantation.
6 After surgical trauma, inflammation (such as corneal transplant rejection) or degenerative disease, human endothelium responds to cell loss by cell migration and spreading rather than by mitosis. If EC density is reduced below approximately 400 cells/mm
2, the monolayer decompensates and aqueous humor enters the stroma, resulting in corneal edema, the irreversible loss of transparency, and, ultimately, blindness.
7 The only treatment to restore vision in such eyes is replacement of whole-thickness cornea (i.e., epithelium, stroma, and endothelium) with a corneal transplant. The impact of endothelial decompensation is indicated by the fact that corneal disease restricted to that monolayer that is sufficient to cause loss of vision is the cause of more than half of all corneal transplantations
5 8 9 (∼3000 per year of which are performed in the United Kingdom and ∼40,000 in the United States).